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Abstract 
Curcumin has long been known to posses medicinal properties and recent scientific studies have shown its efficacy 
in treating cancer. Curcumin is now considered to be a promising anti-cancer agent and studies continue on its 
molecular mechanism of action. Curcumin has been shown to act in a multi-faceted manner by targeting the classical 
hallmarks of cancer like sustained proliferation, evasion of apoptosis, sustained angiogenesis, insensitivity to growth 
inhibitors, tissue invasion and metastasis etc. However, one of the emerging hallmarks of cancer is the avoidance of 
immune system by tumors. Growing tumors adopt several strategies to escape immune surveillance and successfully 
develop in the body. In this review we highlight the recent studies that show that curcumin also targets this process 
and helps restore the immune activity against cancer. Curcumin mediates several processes like restoration of CD4+/
CD8+ T cell populations, reversal of type-2 cytokine bias, reduction of Treg cell population and suppression of T cell 
apoptosis; all these help to resurrect tumor immune surveillance that leads to tumor regression. Thus interaction of 
curcumin with the immune system is also an important feature of its multi-faceted modes of action against cancer. 
Finally, we also point out the drawbacks of and difficulties in curcumin administration and indicate the use of nano-
formulations of curcumin for better therapeutic efficacy.
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Background
Turmeric is one of the most widely used spice ingredi-
ent, derived from Curcuma longa, of the Zingiberacea 
(Ginger) plant family. Some fractions of turmeric, col-
lectively known as curcuminoids (curcumin, demethoxy-
curcumin and bisdemethoxycurcumin) are considered to 
be the active compounds. Curcumin or diferuloylmeth-
ane, having molecular weight 368.38, is primary active 
polyphenolic compounds studied in a host of areas. It 
is an orange-yellow, crystalline powder and insoluble in 
water; however, it is highly soluble in ethanol and DMSO 
[1]. It is used as a spice to give the specific flavor and yel-
low color to curry. Curcumin has been used extensively 
in Ayurvedic medicine for centuries in India and South 
Asia, as it is nontoxic and has several beneficial prop-
erties like anti-oxidant, analgesic, anti-inflammatory 
and antiseptic activity. Curcumin has been used as a 
traditional medicine to treat a spectrum of diseases like 
rheumatism, body ache, skin diseases, intestinal worms, 
diarrhea, intermittent fevers, hepatic disorders, bilious-
ness, inflammations, constipation, leukoderma, amenor-
rhea, arthritis, colitis and hepatitis [2–5]. More recently 
curcumin has been found to have anti-cancer proper-
ties that affect a variety of biological pathways involved 
in mutagenesis, oncogene expression, cell cycle regula-
tion, apoptosis, angiogenesis and metastasis [3–5]. Sev-
eral studies were conducted to explore the anti-cancer 
properties of curcumin and it was shown that curcumin 
modulates multiple cell signaling pathways which include 
cell proliferation (Cyclin D1, c-MYC), cell survival (BCL-
2, BCL-XL, FLIP, XIAP, C-IAP1), apoptosis or cell death 
(Caspase-8, 3, 9), as well as controls tumor suppressor 
pathway (p53, p21) death receptor pathway (DR4, DR5), 
mitochondrial pathways, and protein kinase pathway 
(MAPK, JNK, AKT, and AMPK), thereby affecting tumor 
cell growth [4, 6–8].
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Curcumin against the hallmarks of cancer
Recently it was suggested that tumors share several com-
mon traits (hallmarks) during malignancy that govern 
the transformation of normal cells to cancer cells. In 2000 
Hanahan and Weinberg first proposed that six biologi-
cal properties of cancer cells comprise the hallmarks of 
cancer that are required for the multistep development of 
human cancer. Interestingly, curcumin can inhibit all the 
six major capabilities of cancer cells and restricts tumor 
outgrowth in the host [9].
Curcumin perturbs proliferation signalling
Curcumin inhibits several cell proliferation signalling 
pathways that are relentlessly upregulated in the pro-
gression of cancer. Curcumin inhibits the expression 
of nuclear factor NFκB that regulates cell proliferation, 
metastasis, angiogenesis, apoptosis and resistance to 
chemotherapy [10]. Curcumin-induced down-regulation 
of NFκB is mediated through suppression of IκB kinase 
activation. The proliferation signaling cascades such 
as PI3K, AKT, mTOR, AP1 (JUN and FOS), JNK, JAK-
STAT, PKC, CMYC, MAPK, ELK, CDKs, iNOS and Wnt/
β-catenin which are also suppressed by curcumin further 
confirmed that it is one of the crucial molecule that pre-
vents cancer progression by targeting multiple cell pro-
liferation signalling. Curcumin also down-regulates the 
expression of Cyclin D1, the proto-oncogenes that are 
overexpressed in several types of cancer and plays a cru-
cial role in cell cycle progression and proliferation [11, 
12].
Curcumin causes growth suppression
In addition to capabilities of inducing and sustaining 
positive growth stimulatory signals, cancer cells must 
also avoid the mechanisms that negatively regulate cell 
proliferation by predominantly inhibiting the function of 
tumor suppressor genes. TP53 is the most crucial protein 
that operates on central regulatory circuits which govern 
the decision of cells whether to proliferate or undergo 
active senescence and trigger apoptosis program. Sev-
eral in vitro and in vivo studies confirmed that curcumin 
upregulates the expression of TP53 and induces apopto-
sis [13]. Curcumin also inhibits phosphorylation of RB 
(Retinoblastoma), another important tumor suppressor 
protein that also plays an important role in cell cycle pro-
cess [14]. Curcumin inhibits EGF- and EGFR-mediated 
signalling pathway that is overexpressed in breast tumor 
and is involved in cancer progression [15, 16]. Cur-
cumin also blocks excessive TGFβ receptor signalling 
that induces epithelial to mesenchymal transition during 
invasion and metastasis process [17, 18].
Curcumin in recovering the resistance towards cell death
Tumor cells exploit a variety of strategies to limit or cir-
cumvent apoptosis. During tumor progression, the tumor 
suppressor protein, TP53 is depleted thus hampering 
its critical function as damage sensor and activator of 
apoptosis-inducing circuitry. Alternatively, tumors may 
achieve similar ends by increasing expression of anti-
apoptotic regulators (BCL-2, BCL-XL) or survival signals 
(IGF1/2), or down regulating pro-apoptotic factors (BAX, 
BIM, PUMA), or by short-circuiting the extrinsic ligand-
induced death pathway [19]. Curcumin elicits both TP53-
dependent and -independent cancer cell apoptosis. The 
pro-apoptotic molecules such as BAX, BIM, PUMA are 
upregulated whereas anti-apoptotic partners like BCL2, 
BCL-XL, Survivin are down-regulated by curcumin that 
simultaneously activates Caspases and induces apoptosis 
or programmed cell death [20–23]. Curcumin also acti-
vates lysosomal proteases, phosphatases and lipases that 
trigger autophagy-mediated cell death [24, 25].
Curcumin prevents angiogenesis
Like a normal cell, tumor also requires nutrients as well 
as oxygen and releases excess amounts of carbon diox-
ide for maintaining uncontrolled outgrowth. The tumor-
generated angiogenesis process, fulfil all these essential 
needs. The angiogenic factors like VEGF and angiopoie-
tin induces and operate overall neo-angiogenesis process. 
Curcumin constrains VEGF and angiopoietin over-
expression and prevents angiogenesis process by cut-
ting off food and oxygen supply to the cancer cells [26]. 
Curcumin also inhibits VEGF receptor (VEGFR1 and 
VEGFR2) expression, thereby blocking VEGF/VEGFR-
mediated signalling pathway to restrict angiogenesis [13].
Curcumin restricts replicative immortalities
The maintenance of telomere region is another essential 
hallmark that is required for relentless cell growth and 
cell senescence. The telomerase is activated during can-
cer progression which prevents telomere shortening and 
activate cell proliferative signal continuously. Curcumin 
inhibits human telomerase (hTERT) activities and down-
regulates hTERT-mRNA expression leading to telomere 
shortening. Therefore curcumin targets telomerase activ-
ities and controls replicative cell senescence and mortal-
ity that ultimately regulate uncontrolled cell proliferative 
potential of cancer [27].
Curcumin constrains activation of metastasis and invasion
Tumor continues its invasive outgrowth and migrates to 
other distant sites by invading extracellular matrix via 
metastasis and invasion. Curcumin significantly inhibits 
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cell migration, invasion, and colony formation in  vitro 
and reduces tumor growth and metastasis in  vivo. Cur-
cumin down-regulates several invasion, cell adhesion 
and extracellular matrix molecules such as matrix met-
alloprotease, CCRX4, COX2, ELAM1, ECAM1 that 
are essential for sustaining metastasis [28]. In addition, 
several reports also suggested that curcumin hinders 
the activities of SLUG, SNAIL, FAK, TWIST and other 
essential transcription factors that play a crucial role in 
metastasis process [29]. Recently, it was found that cur-
cumin inhibits breast cancer stem cell migration by 
amplifying E-cadherin/beta-catenin negative feedback 
loop [30] (Fig. 1).
Avoidance of immune system: an emerging 
hallmark of cancer
In order to restrict potential tumor outgrowth the verte-
brates possess distinct and special class of cells that can 
recognize and elicit specific immune response to eradi-
cate neoplastic cells from the host body. The tumor cells 
are smart enough and exploit several strategies to escape 
immune surveillance and thwart the immune system to 
grow continuously and establish tumor immune evasion. 
The tumor-associated antigens (TAA) are not specifi-
cally neo-antigens that are exclusively expressed in tumor 
cells; rather they are tissue differentiation antigens also 
expressed in certain normal healthy cells. The nonspecific 
tumor antigens do not elicit proper immune responses 
and they are also concealed within the stroma. The innate 
immunity which mainly consists of antigen presenting 
cells (dendritic cells, macrophages) and natural killer cells 
(NK and NKT cells) become tolerogenic and are depleted 
due to apoptosis at the advanced stages of cancer. The 
adaptive immune response which mainly comprises of 
T cells (CTLs and Th1 cells), undergo apoptosis and the 
presence of immunosuppressive cytokines renders them 
unresponsive to interactions with antigen presenting cells 
[31, 32]. This creates an environment that is suitable for 
tumor outgrowth [33, 34]. In addition, release of sev-
eral immunosuppressive factors induces generation of 
T-regulatory cell, tolerogenic macrophages and dendritic 
cells that accelerate the tumor immune evasion process 
Fig. 1 Curcumin targets the classical hallmarks of cancer: curcumin has been shown to target all the classical hallmarks of cancer. It reduces 
proliferative signals by interfering with pathways like NFκB, PI3K, MAPK etc. It also restores the levels of growth suppressors like TP53 and retinoblas-
toma protein (RB). Curcumin increases pro-apoptotic proteins like BAX, BIM, PUMA while decreasing anti-apoptotic proteins like BCL-2, BCL-XL, thus 
promoting apoptosis of cancer cells. Curcumin reduces angiogenesis by decreasing VEGF and angiopoetin and interfering with VEGFR signaling. 
Curcumin also restricts replicative immortality by reducing activity of human telomerase (hTERT). Finally curcumin reduces metastasis by targeting a 
host of invasion and cell adhesion related molecules like MMP, CXCR4, SLUG, SNAIL etc.
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rapidly. The immune-surveillance strategy becomes para-
lyzed and subsequently helps in the unrestricted growth 
of tumor cells [35].
In the last decades, research has also progressed about 
using curcumin not only as a therapeutic agent that tar-
gets several signalling-pathways in cancer but also as 
an immune modulator that boosts the immune system 
so that destruction and elimination of cancer cells from 
the host occurs at an early stage thereby preventing 
its disastrous outgrowth. In this review, we will discuss 
the immune editing process that is involved in tumor 
immune evasion and the role of curcumin to re-establish 
tumor immune surveillance from tumor immune escape.
The 3E’s of immunoediting
It has been an age-old hypothesis that the immune sys-
tem can recognize the formation of nascent tumors in 
the body and combat against them. Experimental evi-
dences have poured in through the years to strengthen 
this hypothesis and the process has been referred as can-
cer immune surveillance. Finally, the necessity of avoid-
ing the immune destruction for cancers to develop in 
the body was recognized as a hallmark of cancer devel-
opment by cancer biologists Hannahan and Weinberg 
in [36]. The first prediction about cancer immune-sur-
veillance was put forward by Paul Ehrlich as early as in 
1909. Ehrlich hypothesized that the immune system 
must be preventing the growth of tumors, which would 
otherwise be occurring at a much higher frequency [37]. 
Further arguments were put forward by Burnet and 
Thomas about the immunesurveillance hypothesis in the 
1950s [38, 39]. However the immunesurveillance pro-
cess was difficult to establish experimentally, because it 
was an essentially invisible process, naturally occurring 
in the body without profound manifestations. Hence the 
debate regarding the existence of such mechanisms con-
tinued for a few more decades [40]. The development of 
sophisticated experimental techniques, especially knock-
out mice with specific immunodeficiencies finally pro-
vided a stronger ground for theories regarding cancer 
immunesurveillance. In the 1990s, series of experiments 
involving tumor development in mice, deficient in par-
ticular components of immune system started providing 
a clearer picture of the molecular nature of immunesur-
veillance and its role in preventing tumor development 
[41, 42]. However, growing evidence suggests that the 
interaction between immune system and cancer is a more 
dynamic process and immunesurveillance is only a part 
of it. Interactions between immune system and tumor 
cells may also lead to development of a population of low 
immunogenic cells, that are capable of escaping from 
the immunesurveillance and develop into detectable 
tumors [43]. These observations lead to the formulation 
of a broader model termed as immunoediting, put for-
ward by Dunn et  al. [44]. The cancer immunoediting 
model not only incorporates immune surveillance but 
also the dynamic interactions of tumor with both adap-
tive and innate branches of immune system that edit and 
sculpt the intra-tumoral landscape. The immunoediting 
model serves as the most fundamental and comprehen-
sive explanation of the importance of immune system in 
the war against cancer. A detailed understanding of these 
mechanisms is necessary for designing effective immu-
notherapies against cancer. The immunoediting process 
has mainly been divided into three phases: Elimination, 
Equilibrium and Escape; which are together referred as 
the three E’s of immunoediting. Each process represents 
a dynamic state of interaction between the immune sys-
tem and tumor cells that may lead to either development 
or prevention of cancer. The three states are briefly dis-
cussed below:
Elimination The immune system carries out a constant 
surveillance process by which immune cells recognize 
and try to eliminate nascent tumors in the body [45]. 
During the early stages of tumorigenesis, transformed 
oncogenic cells display tumor-specific signals and anti-
gens that are recognized by the immune system [46]. 
Both innate and adaptive immune systems are involved 
in the elimination process. During the growth of tumor, it 
requires blood supply, hence causing remodeling of sur-
rounding stromal cells and formation of new blood ves-
sels. This results in release of inflammatory cytokines like 
IFNγ and IL12 from tumor cells, surrounding stromal 
cells and macrophages. These attract cells of the innate 
immune system like the NK, NKT and γδ T cells lead-
ing to perforin-, FASL- and TRAIL-mediated killing of 
tumor cells [47, 48]. The pro-inflammatory conditions 
also promote maturation of dendritic cells which ingest 
tumor-associated antigens and present them to the adap-
tive immune system. The presented antigens activate the 
CD4+ T cell which in turn recruit TAA-specific CD8+ 
T cells that lead to further killing of tumor cells [49]. In 
the elimination phase, the reactive immune cells success-
fully eradicate nascent tumors and protect the host body. 
Hence in this case the war is won by the immune system 
as it successfully blocks tumor formation.
Equilibrium Some tumor cells may be resistant enough 
to withstand the attack by immune cells and enter into 
a stage of dormancy [50]. Tumor cells adopt variety of 
mechanisms to thwart the constant assault by immune 
cells and thereby a quiescent state is achieved where 
equilibrium exists between tumor proliferation and apop-
tosis [51]. During this phase, the constant onslaughts 
by the immune system may lead to selection of tumor 
cells that are less immunogenic. It is hypothesized that 
the immune system, at this stage provides a selection 
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pressure, especially through IFNγ-mediated cytotoxic-
ity, that kills the highly-immunogenic tumor cells but 
may leave a population of low-immunogenic cells that 
are more resistant to immune cell-mediated killing. The 
cancer cells are highly plastic, accumulating a number of 
genetic mutations. The immune elimination process may 
favor the existence of phenotypes with reduced immuno-
genicity [52]. The dynamic interaction with the immune 
system shapes the outcome of the process. Depending 
on the circumstances, this equilibrium may shift either 
towards elimination of tumor cells or towards their 
escape from immunesurvillance. This phase is considered 
to be the longest phase of immunoediting and may last 
for months to years [53]. A practical example of the equi-
librium phase is observed in organ transplant cases. One 
study reported the occurrence of metastatic melanoma 
in kidney transplant recipients from a donor, who had 
been previously treated for melanoma, but was consid-
ered tumor free at the time of donation. This suggested 
that immunosuppressive conditions in the recipients may 
have facilitated the growth of tumors that were hidden or 
suppressed in the donor because an intact immune sys-
tem in the donor kept them at an equilibrium state [54].
Escape The escape phase ensues when the battle is 
won by the tumor cells and is marked by development of 
clinically detectable tumors [55, 56]. The high-plasticity 
of tumor cells allow them to modify themselves enough 
to avoid the immune system. An important strategy of 
tumor cells to avoid destruction by immune system is to 
create an immunosuppressive environment by secretion 
of highly immunosuppressive cytokines such as TGFβ, 
IL10 [57]. Some tumor cells overproduce molecules like 
galectin, indoleamine 2-3-dioxygenase, which block 
T cell response and induce T cell apoptosis. They also 
release pro-inflammatory signals which block dendritic 
cell maturation [58, 59]. Another important strategy for 
immune escape is the induction of CD4+CD25+FOXP3+ 
T-regulatory (Treg) cells. Treg cells have the ability to 
suppress the immune system by adding to the pool of 
TGFβ and IL10, induction of T cell apoptosis by IL2 
depletion, decreased co-stimulation and maturation of 
dendritic cells [60] (Fig. 2).
Curcumin: general effects on the immune system
Curcumin, known for its therapeutic effects, especially 
in cancer, is also recognized as a potent modulator of 
the immune system. Curcumin has been shown to exert 
immunomodulatory effects on several cells and organs of 
the immune system [61].
T cells Several studies have reported that curcumin 
can modulate the proliferation and activation of T cells. 
It has been reported that curcumin reduces the prolifera-
tion of T cells induced by compounds like concanavalin 
A (Con A), phytohemagglutinin (PHA), and phorbol-
12-myristate-13-acetate (PMA) [62]. It has also been 
shown to reduce IL2 production via modulation of NFκB 
pathway [63]. It can both suppress and stimulate the pro-
liferation of T cells depending on the context and dose of 
administration. Studies by Tomita et al. have shown that 
curcumin can specifically block proliferation of HTLV-1 
infected T cells and primary ATL cells through cell cycle 
arrests by down-regulating Cyclin D1, Cdk1, and Cdc25C 
and induction of apoptosis by down-regulating XIAP and 
survivin [64, 65]. Another study by Hussain et  al. car-
ried out in T cell acute lymphoblastic leukemia showed 
that curcumin suppresses constitutively activated targets 
of PI3-kinase (AKT, FOXO and GSK3) in T cells lead-
ing to the inhibition of proliferation and induction of 
caspase-dependent apoptosis [66]. However other study 
suggested that the effect of curcumin on T cells was 
dose-dependent; low-dose curcumin increased the pro-
liferation of splenic lymphocytes, whereas high-dose cur-
cumin depressed it in mice [67].
B-cells Curcumin has also been shown to regulate other 
cells of the immune system. It has been shown to prohibit 
proliferation of B-cell lymphoma cells via down-regula-
tion of c-MYC, BCL-XL and NFκB activities [68]. It has 
also been reported to block Epstein Barr Virus (EBV)-
induced immortalization of B-cells [69].
Macrophages Curcumin has been shown to modulate 
macrophage activities and inhibit generation of ROS in 
macrophages. It promotes enhanced phagocytosis of per-
itoneal macrophages in mice [70].
NK cells Curcumin is also effective against natural killer 
T cell lymphoma cell lines, where it promotes apoptosis 
by regulating the NFκB pathway and blockage of BCL-
XL, Cyclin D1 etc. [71].
Dendritic cells Kim et  al. reported that curcumin can 
suppress expression of CD80, CD86 and class-II antigens 
by dendritic cells. Curcumin also blocked the release of 
inflammatory cytokines like IL1β, IL6 and TNFα from 
LPS-stimulated dendritic cells. Curcumin was shown to 
modulate phosphorylation of MAPK and nuclear translo-
cation of NFκB in dendritc cells [72].
Curcumin and anti‑tumor immune response:
Apart from the direct effect of curcumin in reducing 
proliferation of various immune cell or lymphomas, 
there are plenty of evidences suggest that curcumin can 
enhance anti-tumor immunity, thereby tilting the bal-
ance in favor of immune system-mediated eradication of 
tumor. Hence it would be interesting to envisage the role 
of curcumin with respect to the immunoediting process 
described earlier. As mentioned earlier, tumor growth 
is associated with escape of immunosurveillance pro-
cesses and causes a general immunosuppression in the 
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Fig. 2 The 3 E’s of tumor immunoediting: tumor formation occurs through accumulation of mutations induced by various stress factors like radia-
tion, virus, chemicals and other carcinogens. During initial tumor growth, the tumor cells undergo dynamic interactions with the immune system, 
which is called tumor immunoediting and can be divided into 3 distinct phases. I. Elimination In this phase the balance is tilted towards the immune 
system. Large numbers of CD8+, CD4+ T cells along with NK-cells, macrophages and dendritic cells mount an effective response to the tumor. 
Soluble factors like IFNγ, perforin, granzyme lead to tumor cell apoptosis and elimination of cancer. II. Equilibrium In this phase an equilibrium exists 
between the tumor and immune system. The immune system tries to shift the balance towards elimination whereas the tumor cells also apply 
mechanisms to avoid immunesurveillance. III. Escape The continuous assault by the immune system may lead to development of tumor cells that 
are less immunogenic and can avoid the immune system. The tumor has several strategies to escape the immune system; these include induction 
of T cell apoptosis, blocking dendritic cell maturation and promoting generation of immunosuppressive Treg cells. Hence the balance shifts towards 
the tumor and tumor development can occur unhindered
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body. This is manifested by lower percentages of effec-
tor T cells (CD4+ and CD8+) and a shift from Th1 to Th2 
type cytokine production, leading to decreased activity 
of cytotoxic T lymphocytes (CTLs) [73]. This is accom-
panied by an increase in levels of Treg cells which have 
an inhibitory effect on the immune system by secreting 
anti-inflammatory cytokines like TGFβ and IL10 [74]. 
Th1 type immune response is considered to be appro-
priate for fighting against cancer. IL2 and IFNγ are two 
Th1 type cytokines that promote survival, activation and 
proliferation of CTLs as well as helper T cells [75]. Hence 
presence of these cytokines is essential for development 
of robust anti-tumor responses. Th2 response on the 
other hand is inappropriate towards tumor as it fails to 
destroy tumor cells and inhibits cell-mediated immunity 
[76].
Restoration of CD4+ and CD8+ T cell populations
Sa and co-workers showed that curcumin is effective in 
restoring populations of CD4+ and CD8+ cells in the 
tumor microenvironment and thereby driving the Th2 
cytokine bias towards a Th1 type response again [77, 78]. 
Curcumin efficiently restored CD4+ and CD8+ popu-
lations in all immune compartments of tumor-bearing 
mice. The study also showed that curcumin administra-
tion prevented depletion of central memory and effector 
memory T cell. The presence of increased population of 
tumor infiltrating lymphocytes leads to increased tumor-
cell killing, thereby eliminating the tumor from the body.
Increased Th1 type response
The observed reduction of Th1 cytokines like IFNγ and 
increased type-2 cytokines like IL4 during cancer pro-
gression was also reversed by curcumin. Some reports 
however suggest that curcumin favors a Th2-type 
response while others report that curcumin promotes 
cancer regression by restoring Th1 immune responses 
[79]. Gertsch et  al. for example showed that curcumin 
has the ability to upregulate IFNγ mRNA expression, 
which is a type-1 cytokine [80]. These apparently contra-
dicting reports suggest that curcumin may be involved 
in perturbing complex signaling networks, making its 
function context-dependant. Curcumin modulates the 
complex array of signals during the interaction between 
tumor cells and the immune system to finally leading to 
an enhanced anti-tumor immunity.
Reduction of T‑regulatory cell population
Another important player in the tumor immune evasion 
process is the CD4+CD25+FOXP3+ T-regulatory cells 
(Tregs). These cells in general have an immunosuppres-
sive function and are necessary for prevention of autoim-
mune disorders [81]. Progression of tumor is associated 
with an increase in Treg cell population which secrete 
immunosuppressive cytokines like TGFβ and IL10. Treg 
not only secrete immunosuppressive cytokines, they 
also express the high-affinity IL2 receptor CD25, which 
sequesters IL2 from the tumor milieu. Since IL2 is essen-
tial for survival and proliferation of other T cells, unavail-
ability of the cytokine leads to effector T cell apoptosis 
[82]. The presence of Treg cells in the tumor microenvi-
ronment correlates with poor prognosis of cancer [83]. 
Bhattacharya et al. showed that curcumin can effectively 
reduce Treg cell population and levels of IL10 and TGFβ 
[84]. Other studies also reported similar results, show-
ing that pretreatment of CD4+CD25+ Treg cells with 
curcumin reduced their immunosuppressive activity [85, 
86]. FOXP3 and CTLA4 are two of the key transcription 
factors that are involved in regulating the Treg transcrip-
tional program and are essential for Treg development 
and function [87]. This study also showed that curcumin 
can reduce expression of CTLA4 and FOXP3 both at pro-
tein and mRNA levels. Hence curcumin has been shown 
to modulate the interaction between immune system and 
tumor cells, restoring the ability of the immune system to 
successfully eliminate tumor cells.
Reduced T cell apoptosis
Several other studies also confirmed that curcumin has 
a positive effect on anti-tumor immunity. Varalakshmi 
et  al. reported that prolonged injections of curcumin 
did not have any detrimental effects on the immune sys-
tem; rather they maintained the levels of Th1 cytokine 
production, NK cell cytotoxic activity and generation of 
reactive oxygen species and nitric oxide by macrophages 
[85]. In-vivo studies involving mice bearing ascites car-
cinoma cells also show similar effects of curcumin on 
the immune system. It has been shown that administra-
tion of curcumin in tumor-bearing mice leads to inhi-
bition of tumor-induced apoptosis in both thymocytes 
and splenocytes, thereby restoring immune cell numbers 
and successful regression of tumor [77]. Other studies 
tried to delineate the molecular mechanisms affected by 
curcumin in immune cells. The JAK3-STAT5a pathway 
is responsible for maintaining levels of the anti-apop-
totic protein BCL-2 in T cells and its impairment dur-
ing cancer leads to decreased BCL-2 levels. This in turn 
increases pro-apoptotic protein BAX, which is responsi-
ble for tumor-induced T cell death. It has been reported 
that curcumin can successfully restore the phosphoryla-
tion and activation of the JAK3-STAT5a pathway in T 
cells and activation of this pathway restores the level of 
BCL-2, thus reducing T cell apoptosis in tumor-bearing 
mice [88]. Studies also suggested that curcumin prevents 
tumor-induced thymic atrophy by restoring activity of 
the NFκB pathway [89]. Luo et al. reported that the effect 
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of curcumin was dependent on the dose of curcumin 
administered. Both in vivo and in vitro studies confirmed 
that a low-dose of curcumin induced effective anti-tumor 
response by increasing CD8+ cytotoxic T cells and IFNγ 
secretion; whereas a higher-dose of curcumin was detri-
mental for T cells [90] (Fig. 3).
Major drawbacks of curcumin
Although curcumin has been used as a most reliable, safe 
and promising agent with high-efficacy for cancer ther-
apy and chemoprevention but it is not well accepted as 
a “panacea for all ills” in cancer community. It is feebly 
soluble in water and it has been reported that solubil-
ity of curcumin persisted only approximately 11  ng/ml 
in aqueous solution (pH = 5.0) [91]. Such poor aqueous 
solubility creates difficulties in oral administration of cur-
cumin. Curcumin is rapidly hydrolyzed and degraded in 
neutral and alkaline condition but shows greater solubil-
ity in acidic environments. Moreover, rapid metabolism 
and fast systemic elimination are essential key factors 
that lead to reduced systemic bioavailability [92–95]. It 
has been shown that after intraperitoneal or intravenous 
administration of curcumin, excess amounts of the drug 
was excreted through bile in the form of tetrahydrocur-
cumin and hexahydrocurcumin glucuronides derivatives 
[96, 97]. The reduced bioavailability of orally adminis-
trated curcumin in GI tract (i.e. colorectum) limits its 
therapeutic efficacy against cancer immunosuppres-
sion [98, 99]. In a Phase-I clinical trial, colorectal cancer 
patients at advance metastasis stages were administered 
3600 mg of oral curcumin daily, and levels of curcumin 
and its metabolites were measured by HPLC in portal 
and peripheral blood [100]. It was found that curcumin 
was poorly accessible after oral administration, with little 
amounts (nanomolar levels) existing as the parent com-
pound and its metabolite derivatives like glucuronide and 
sulphate conjugates in the peripheral or portal circula-
tion. Similarly, in another Phase-I study, 8000 mg of free 
curcumin were introduced into cancer patients orally per 
day but only minute levels were detected in portal vein 
and peripheral systems further highlighting its limita-
tions [101]. In other clinical trial it has been shown that 
increment of curcumin doses gradually from 500 to 
8000  mg/day was not detectable in their bloodstream 
Fig. 3 Curcumin enhances anti-tumor immunity: Curcumin can boost anti-tumor immunity through different mechanisms. These include: 
increased population of CD8+, andCD4+ T cells, along with increase in Th1 cytokines like IFNγ, which mediate tumor cell apoptosis. Curcumin can 
block Treg cell development, thereby decreasing immunosuppressive cytokines like IL10 and TGFβ. Curcumin also reduces tumor-induced T cell 
apoptosis. All these processes help to nullify the overall immunosppressive environment created by tumor and lead to tumor regression. Thus 
curcumin has the ability to shift the balance in favor of the immune system and reinstate immune system-mediated elimination of tumors
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and only trace amounts of its derivatives were found in 
the patients who consumed 10,000 mg to 12,000 mg/day 
[102, 103]. Therefore it is necessary to develop an alterna-
tive and efficient strategy to improve solubility and bioa-
vailability of curcumin for a better therapeutic substitute 
against tumor induced immunosuppression.
Curcumin nano formulation: future perspectives
Although curcumin acts as a potent immune-modula-
tor, but poor water solubility, low bioavailability, lack 
of dose–response proportionality, uncontrolled pre-
cipitation, use of excessive co-solvents, necessity of 
extreme condition to solubilize (basic or acidic) and 
Fig. 4 Different strategies of curcumin nano formulation preparation: (1) Liposomes Lipophilic particles are incorporated into the hydrocarbon 
bilayer whereas hydrophilic molecules are incorporated into their aqueous interiors. (2) Polymeric micelles They contain both hydrophilic and 
hydrophobic functional groups and are hence called amphiphiles. They are formed when the concentration of amphiphiles exceeds critical micelle 
concentration. (3) Polymer nanoparticles Consist of intense matrix structure that can incorporate the pharmacologically active ingredients and has 
a high-drug loading capacity. (4) Nanogels A core shell polystyrene gel layer structure consisted of inner hydrophobic core that interacted with 
active pharmacological substances for high-drug yields and PEG analogue outer shell that trigger fast release of preloaded drug. (5) Nanoemul-
sion Thermodynamically stable dispersion of water and oil, stabilized with active surface film consist of surfactant and cotransfactent. (6) Solid lipid 
nanoparticles consist of solid lipid core matrix that stabilized by surfactants or emulsifier and solubilize lipophilic substances. (7) Inclusion complex: 
mixture of active drug ingredients primarily located in the hydrophobic cavity of bulky host molecules such as cyclodextrin. (8) Dendrimer Core–
shell nanostructure generally synthesized in layer-by layer fashion where many pharmaceutical active compounds directly associated with stable 
physical interaction or chemical bonding. (9) Phytosomes: The phospholipid complex, obtained by pure phospholipids containing biological deriva-
tives with active pure ingredients with definite physicochemical and spectroscopic properties. (10) Curcumin nanoparticles These are nanoparticles 
made from pure curcumin without any carrier conjugates. They are prepared by dissolving pure curcumin in ethanol and homogenization at high 
pressure with water containing 0.1 % citric acid [86]
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incompatibility to the patients are some of the major 
hurdles that hampers its efficacy as a chemotherapeutic 
drug against cancer [104, 105]. To overcome such incon-
veniences nanotechnology-based drug delivery systems 
have proven to be most reliable and promising approach. 
Nanotechnology-based drug delivery systems improve 
poor bioavailability, enhance biological activities and also 
selectively target cancer cells. To enhance systematic bio-
availability of higher molecular weight drugs, it is now 
possible to deliver the active pharmaceutical ingredient 
as reduced nano-sized particles, ranging in size from 
10 to 1000  nm. The nanotechnology-based drug deliv-
ery system has been proven as a most effective method 
to successfully deliver insoluble drugs with enhanced 
bioavailability [106]. The reduction of particle size of 
active ingredients significantly enhances the dissolution 
rate resulting in higher bioavailability. Several forms of 
nanoparticles are being developed for successful encap-
sulation of curcumin. These include liposomes, nanopar-
ticles, micelles, nanogels, nanoemulsions, nanocrystal 
suspensions, phytosome complexes, inclusion complexes 
and dendrimer/dimers [107]. Recently, instead of carrier-
based nano formulations, pure curcumin nanoparticles 
have been developed that are 50 times more effective 
than normal curcumin, with increased bioavailability. 
These curcumin nanoparticles restrict tumor-induced 
Treg cells by inhibiting several Treg markers and restore 
immune surveillance in tumor-bearing mice [86].
Although, nanotechnology based drug delivery sys-
tem has been proven as a major effective and promising 
approach towards successful cancer therapy but there 
are also certain limitations. Difficulties such as possibil-
ity of drug targeting, drug-loading capacity, in  vivo fate 
of the carrier-molecule conjugates (interactions with the 
biological microenvironment, rate of disintegration and 
accumulation in organs), toxic effects of the carrier mol-
ecule or its metabolites, its large scale production, stabil-
ity during long-term storage and overall production costs 
are difficult to deal with. Especially, the toxic effects of 
the nano-formulations in the body are a critical param-
eter. Although the carrier materials are tested for toxicity 
and biocompatibility, however the properties of the nano 
particles often differ from bulk material. Hence rigor-
ous and specialised tests for determining the toxicities of 
the carrier molecules, its metabolites and surfactants are 
necessary before approval for use [104] (Fig. 4).
Conclusion
Curcumin is thus found to be an extremely promising 
anti-cancer agent, targeting various pathways associated 
with cancer progression. Studies continue to reveal new 
sides of its mode of action and its interaction with the 
immune system is emerging as an important contributor 
to its anti-cancer properties. The need for tumor cells to 
avoid the immune system during successful tumor pro-
gression in the body is now considered to be a new hall-
mark of cancer. Various studies in the past decade have 
gradually established curcumin as a potent immune-
modulator. Although some reports have suggested a 
general immunosuppressive role of curcumin and its 
ability to reduce cell proliferation in immune cell in iso-
lation; specific reports suggest that curcumin boosts 
anti-tumor immunity through various mechanisms, as 
discussed in this review. Thus modulation of the immune 
system seems to be another important strategy by which 
curcumin counteracts cancer development. This fur-
ther asserts its effectiveness as an anti-cancer agent and 
points out the need to develop it as an adjuvant chemo-
therapeutic agent. This necessitates the development of 
nano-based strategies for proper delivery and increased 
bioavailability of curcumin, which may finally lead to its 
use as a proper chemotherapeutic agent.
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